Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
3.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239405
4.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 21(1): 33-41.e16, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634607
5.
COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020.
Int J Cancer
; 151(9): 1502-1511, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35704342
6.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
7.
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.
Semin Cancer Biol
; 60: 344-350, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31626958
8.
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
J Natl Compr Canc Netw
; 19(2): 181-189, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33401235
9.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109233
10.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969184
11.
Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study.
Breast J
; 26(2): 188-196, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31448501
12.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085669
13.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31796073
14.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
15.
DESTINY-Breast03 trial: some questions remain.
Lancet
; 401(10389): 1653, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210116
16.
How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Semin Cancer Biol
; 44: 106-116, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28442298
17.
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.
Br J Cancer
; 119(12): 1487-1494, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478407
18.
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Breast Cancer Res Treat
; 168(3): 631-638, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29280043
19.
Advancing immunotherapy for early-stage triple-negative breast cancer.
Lancet
; 396(10257): 1046-1048, 2020 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966831
20.
Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
Breast Cancer Res Treat
; 160(3): 425-437, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770282